Cognitive and Pharmacodynamic Testing in CNS First-In-Human Trials

A New Trend in Early-Phase CNS Trials

Watch this on-demand webinar on which we collaborated with Cambridge Cognition, to learn about the important role of cognitive and pharmacodynamic testing in first-in-human (FIH) trials for novel CNS-active drugs.

Recently, we have seen increasing numbers of complex FIH studies in CNS-active drugs to gather comprehensive data with a wider range of doses as early as possible. Insights in FIH studies provide valuable information on potential dosing, efficacy, and safety, and serve as a good guide for the regulatory requirements needed throughout clinical development.

WATCH THE VIDEO

You may also be interested in these resources:

Webpage:

• CNS Drug Development Solutions

Webinars:

• Inside the Pharmacodynamic Toolbox
• A Review of the FDA's Psychedelic Clinical Research Guidances